Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 71Observational 1

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Melanoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × aldesleukin × Genitourinary × Clear all
NCT00617799 2023-10-10

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

University of Nebraska

Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡